|
1) Van den Berghe H, Cassiman JJ, David G, et al. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature. 1974; 251: 437-8
|
|
|
|
2) Hasserjian RP, Le Beau MM, List AF, et al. Myelodysplastic syndrome with isolated del(5). In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th ed. International Agency for Research on Cancer. Lyon: IARC Press; 2008. p.102
|
|
|
|
|
|
3) Boultwood J, Fidler C, Strickson AJ, et al. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood. 2002; 99: 4638-41
|
|
|
|
|
|
4) Ebert BL. Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer. Leukemia. 2009; 23: 1252-6
|
|
|
|
|
|
5) List A, Dewald G, Bennett J, et al. Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006; 355: 1456-65
|
|
|
|
|
|
6) Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature. 2008; 451: 335-9
|
|
|
|
|
|
7) Draptchinskaia N, Gustavsson P, Andersson B, et al. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat Genet. 1999; 21: 169-75
|
|
|
|
|
|
8) Gazda HT, Grabowska A, Merida-Long LB, et al. Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia. Am J Hum Genet. 2006; 79: 1110-8
|
|
|
|
|
|
9) Doherty L, Sheen MR, Vlachos A, et al. Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia. Am J Hum Genet. 2010; 86: 222-8
|
|
|
|
|
|
10) Barlow JL, Drynan LF, Hewett DR, et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med. 2010; 16: 59-66
|
|
|
|
|
|
11) Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med. 2010; 16: 49-58
|
|
|
|
|
|
12) Liu TX, Becker MW, Jelinek J, et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nature Med. 2007; 13: 78-83
|
|
|
|
|
|
13) Pellagatti A, Jädersten M, Forsblom AM, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A. 2007; 104: 11406-11
|
|
|
|
|
|
14) Joslin JM, Fernald AA, Tennant TR, et al. Haploinsufficiency of EGR1, a candidate gene in the del (5q), leads to the development of myeloid disorders. Blood. 2007; 110: 719-26
|
|
|
|
|
|
15) Wei S, Chen X, Rocha K, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A. 2009; 106: 12974-9
|
|
|
|
|
|
16) Boultwood J, Pellagatti A, Cattan H, et al. Gene expression profiling of CD34＋ cells in patients with the 5q- syndrome. Br J Haematol. 2007; 139: 578-89. Epub 2007 Oct 3
|
|
|
|
|
|
17) Mansell A, Brint E, Gould JA, et al. Mal interacts with tumor necrosis factor receptor-associated factor (TRAF) -6 to mediate NF-kappa B activation by toll-like receptor (TLR) -2 and TLR4. J Biol Chem. 2004; 279: 37227-30
|
|
|
|
|
|
18) Sachdeva M, Zhu S, Wu F, et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A. 2009; 106: 3207-12
|
|
|
|
|